Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Surg Endosc ; 25(11): 3627-35, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21858582

ABSTRACT

BACKGROUND: Although the efficacy and safety of extensive endomucosal resection (EMR) in eradicating Barrett's esophagus (BE) harbouring early neoplasia have been established, factors predicting efficacy remains unclear. AIM: To determine the complete eradication rate of Barrett's esophagus with high-grade intraepithelial neoplasia (HGIN) or intramucosal carcinoma (IMC), safety, and factors predicting complete eradication by EMR. METHODS: Patients with histological confirmation of Barrett's HGIN/IMC were prospectively identified. EMR was performed using Duette multiband ligator or cap technique by a single operator (NEM). RESULTS: 99 patients (81 males) with median age 67 years [interquartile range (IQR) 60-77 years] and median Barrett's length 4 cm (IQR 2-6 cm) were included. Of 628 index EMRs [mean 6.3, median 5 (IQR 3-8)], 23% showed IMC, 58.5% showed HGIN, and 16% showed low-grade dysplasia only. A median of 8 EMR resections per patient (IQR 6-16, 1,064 resections in 89 patients) resulted in complete eradication of BE harboring neoplasia in 49.4% and eradication of HGIN/IMC in 81% (BE <5 cm subgroup: 65% complete eradication and 91% HGIN eradication) at median follow-up of 18 months (range 6-27 months). On univariate analysis, focal dysplasia (P = 0.003) and Barrett's length <5 cm (P = 0.001) were predictors of complete BE eradication. Barrett's length <5 cm was the only significant predictor [odds ratio (OR) 3.4, standard error (SE) 0.11, P = 0.0006] on multiple logistic regression analysis. Strictures developed in 27% and major bleeding in 2% with no procedure-related perforations or mortality. CONCLUSIONS: Extensive EMR for removal of BE with early neoplasia is safe. Outcomes for complete BE eradication are modest at 49.4% and eradication of high-grade dysplasia at 81%. Barrett's length <5 cm is the only significant predictor of complete response.


Subject(s)
Barrett Esophagus/surgery , Carcinoma in Situ/surgery , Esophageal Neoplasms/surgery , Esophagoscopy , Aged , Barrett Esophagus/complications , Barrett Esophagus/pathology , Carcinoma in Situ/complications , Esophageal Neoplasms/complications , Esophagus/pathology , Female , Humans , Male , Middle Aged , Postoperative Complications
2.
Aliment Pharmacol Ther ; 32(6): 821-7, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20629974

ABSTRACT

BACKGROUND: Porfimer is an intravenous (i.v.) injectable photosensitizing agent used in the photodynamic treatment of tumours and of high-grade dysplasia in Barrett's oesophagus. AIM: To assess the pharmacokinetics as well as the safety profiles of porfimer after a first and a second dose administered 30-45 days apart in patients undergoing photodynamic therapy. METHODS: Nineteen patients (16 with cholangiocarcinoma) were enrolled. Porfimer sodium was administered by i.v. injection over 3-5 min. Blood samples were collected prior to starting i.v. drug injection and postdose at different time points after the first and second administrations. RESULTS: Porfimer exposure values after the second administration were statistically higher than those observed after the first administration, suggesting a slight accumulation of porfimer following repeated administration. The apparent mean elimination half-life of porfimer increased from 410 h after the first administration to 725 h after the second administration. The safety profiles of porfimer after a first and a second administration were similar and did not raise additional concern. Eight patients experienced nine serious adverse events. Only photosensitivity was deemed study-drug related. CONCLUSION: Porfimer appears to display a safe and tolerable profile when used in patients requiring a second photodynamic therapy within 45 days.


Subject(s)
Adenocarcinoma/drug therapy , Barrett Esophagus/drug therapy , Dihematoporphyrin Ether/pharmacokinetics , Esophageal Neoplasms/drug therapy , Photosensitizing Agents/pharmacokinetics , Aged , Dihematoporphyrin Ether/administration & dosage , Dihematoporphyrin Ether/adverse effects , Female , Humans , Male , Middle Aged , Photochemotherapy , Photosensitizing Agents/administration & dosage , Photosensitizing Agents/adverse effects , Statistics as Topic , Time Factors , Treatment Outcome
3.
Br J Cancer ; 98(9): 1548-54, 2008 May 06.
Article in English | MEDLINE | ID: mdl-18414413

ABSTRACT

Biliary brush cytology is the standard method of sampling a biliary stricture but has a low sensitivity for the detection of malignancy. We have previously shown that minichromosome maintenance (MCM) replication proteins (Mcm2-7) are markers of dysplasia and have utilised these novel biomarkers of growth for the diagnosis of cervical and bladder cancer. We aimed to determine if MCM proteins are dysregulated in malignant pancreaticobiliary disease and if levels in bile are a sensitive marker of malignancy. In 30 tissue specimens from patients with malignant/benign biliary strictures, we studied Mcm2 and -5 expression by immunohistochemistry. Bile samples were also collected prospectively at endoscopic retrograde cholangiopancreatography from 102 consecutive patients with biliary strictures of established (n=42) or indeterminate aetiology (n=60). Patients with indeterminate strictures also underwent brush cytology as part of standard practice. Bile sediment Mcm5 levels were analysed using an automated immunofluorometric assay. In benign biliary strictures, Mcm2 and -5 protein expression was confined to the basal epithelial proliferative compartment - in contrast to malignant strictures where expression was seen in all tissue layers. The percentage of nuclei positive for Mcm2 was higher in malignant tissue (median 76.5%, range 42-92%) than in benign tissue (median 5%, range 0-33%) (P<0.0005), with similar results for Mcm5. Minichromosome maintenance protein 5 levels in bile were significantly more sensitive than brush cytology (66 vs 20%; P=0.004) for the detection of malignancy in patients with an indeterminate stricture, with a comparable positive predictive value (97 vs 100%; P=ns). In this study, we demonstrate that Mcm5 in bile detected by a simple automated test is a more sensitive indicator of pancreaticobiliary malignancy than routine brush cytology.


Subject(s)
Bile/chemistry , Biliary Tract Neoplasms/diagnosis , Biomarkers, Tumor/analysis , Cell Cycle Proteins/analysis , Nuclear Proteins/analysis , Pancreatic Neoplasms/diagnosis , Adult , Aged , Biliary Tract Neoplasms/chemistry , Cholangiopancreatography, Endoscopic Retrograde , DNA Replication , Female , Fluoroimmunoassay , Humans , Immunohistochemistry , Male , Middle Aged , Minichromosome Maintenance Complex Component 2 , Pancreatic Neoplasms/chemistry , Predictive Value of Tests , Prospective Studies , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...